Status:
ACTIVE_NOT_RECRUITING
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Adult Brain Tumor
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This research trial studies metabolomic and other molecular profiling to identify predictive biomarkers for radiation toxicity and survival in patients with lung or brain cancers receiving radiation t...
Detailed Description
PRIMARY OBJECTIVES: I. Metabolomic and epigenetic urine and blood profiles of patients undergoing radiation therapy for lung cancer associated with the development of radiation pneumonitis. II. Meta...
Eligibility Criteria
Inclusion
- Consultation with the Radiation Oncology department of the Ohio State University (OSU) Comprehensive Cancer Center
- The following diagnoses will be included: malignant neoplasm of the brain; primary malignant neoplasm of trachea bronchus and lung; primary malignant neoplasm of the cervix uteri and primary malignant neoplasm the prostate
Exclusion
- Being an inmate
Key Trial Info
Start Date :
October 4 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
273 Patients enrolled
Trial Details
Trial ID
NCT02259218
Start Date
October 4 2012
End Date
December 31 2025
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States, 43210